

in peripheral smear. On scrotal ultrasonography (USG), the left epididymal head had a mildly heterogeneous appearance and the patient was treated for epididymitis with suspicion of epididymitis. Approximately one week later, the patient presented with fever. The patient's peripheral smear showed 36% blasts, 38% eosinophils, 2% monocytes, 6% lymphocytes, 10% segments and 8% bands. Bone marrow aspiration was performed for the diagnosis of acute leukemia and PreB-ALL was diagnosed. Control testicular USG was evaluated as testicular involvement of leukemia. During follow-up, the patient had nausea, vomiting, dizziness, decreased visual field, nuchal rigidity, and outward gaze limitation. Magnetic resonance (MR) venography revealed thrombosis in the inferior sagittal sinus and anticoagulant therapy was initiated. The patient with central nervous system symptoms was considered to have leukemic involvement and his treatment was adjusted. ALL is a condition that can cause HE. The prognosis is poor in ALL patients presenting with HE. HE may occur before the classical ALL symptoms therefore the diagnosis of ALL should also be considered in patients presenting with HE.

<https://doi.org/10.1016/j.htct.2024.11.031>

PP 04

EVALUATION OF DRUG EFFECTIVENESS AND CONTROLLED RELEASE PROFILES OF CLAY MINERALS LOADED WITH ANTI-CARCINOGENIC AGENT AS A DRUG DELIVERY SYSTEM ON LEUKEMIA


Mustafa Duran^{1,*}, Elif Kağa²

¹ Afyonkarahisar Health Science University, Faculty of Medicine, Department of Internal Medicine Hematology

² Afyonkarahisar Health Science University, Faculty of Medicine Pathology

Objective: This study aimed to evaluate the slow release and internalization of azacitidine-bentonite combination in THP-1 and K562 cell cultures in acute myeloid leukemia morphology. **Methodology:** The morphology of bentonite clay was assessed using two Scanning Electron Microscopes. The bentonite-azacitidine combination was assessed in THP-1 and K562 cell cultures via in vitro cell proliferation tests, proliferation with CCK-8, and drug release tests with dialysis membranes. Additionally, apoptosis and internalization were determined using the Annexin V-FITC Kit and fluorescence methods, respectively. **Results:** Our findings showed that azacitidine achieved complete and controlled release within 8 hours. Bentonite displayed significant antiproliferative effects at concentrations of 10, 25, 50, and 100 $\mu\text{g/ml}$ in both cell lines. The combination of azacitidine and bentonite exhibited a synergistic effect in inhibiting cell proliferation, with significant decreases in cell viability in the 1 μM azacitidine + 10 $\mu\text{g/ml}$ bentonite, 5 μM azacitidine + 10 $\mu\text{g/ml}$ bentonite, and 10 μM azacitidine + 10 $\mu\text{g/ml}$ bentonite groups compared to the controls. The drug release profile of the

bentonite-azacitidine combination demonstrated slow release, with 50% released in the first two hours and approximately 90% released in the fourth hour, with prolonged release exceeding eight hours, potentially reducing side effects and increasing efficacy in target cells. **Conclusion:** In conclusion, bentonite NPs exhibited significant potential as drug carriers for azacitidine in the treatment of leukemia and offered benefits such as improved solubility, bioavailability, controlled release, protection from harsh environments, and cost-effectiveness.



<https://doi.org/10.1016/j.htct.2024.11.032>

PP 05

LIVER INVOLVEMENT IN ACUTE MYELOID LEUKEMIA: A CASE REPORT

Nida Akgül^{1,*}, Ali Doğan¹, Cihan Ural¹, Ramazan İpek¹

¹ Van Yüzüncü Yıl University Faculty of Medicine, Department of Hematology

Objective: Although rare, extramedullary involvement can be observed in patients with acute myeloid leukemia (AML). These extramedullary involvements are also known as myeloid sarcoma, granulocytic sarcoma, or chloroma. The most common sites of involvement are soft tissues, bone, periosteum, and lymph nodes. Patients with extramedullary involvement may exhibit a more aggressive clinical course. In this case report, we evaluated an AML patient with liver involvement at the time of diagnosis. **Case Report:** A 66-year-old female patient presented to our hospital with complaints of fatigue, bruising on the skin, and yellowing of the eyes for about a month. Physical examination revealed icterus in the sclera, and widespread ecchymoses on the arms and abdomen. Laboratory findings showed a hemoglobin level of 7.8 g/dL, a leukocyte count of $4.4 \times 10^9/\text{L}$, a neutrophil count of $1.1 \times 10^9/\text{L}$, a platelet count of $30 \times 10^9/\text{L}$, CRP at 29 mg/L, and direct bilirubin at 5.8 mg/dL. Peripheral blood smear revealed notable myeloblasts and auer rods. Bone marrow aspiration smear showed over 20% myeloblasts, supporting the diagnosis of acute myeloid leukemia. Flow cytometry analysis was evaluated as consistent with AML. Abdominal ultrasonography revealed the liver was 19.5 cm and the spleen was 16 cm in size. The patient underwent 7+3 remission induction